Oramed Pharmaceuticals (ORMP) FCF Margin (2016 - 2025)

Oramed Pharmaceuticals has reported FCF Margin for 8 years, with the latest figure at 176.1% in Q1 2025.

• For the quarter ending Q1 2025, FCF Margin changed N/A year-over-year to 176.1%; the trailing twelve-month figure through Dec 2025 stood at 457.7% (changed N/A YoY), and the FY2025 full-year result was 457.7%, changed N/A from the prior year.
• FCF Margin for Q1 2025 stood at 176.1%, up from 393.77% in the prior quarter.
• The five-year high for FCF Margin was 176.1% in Q1 2025, with the low at 1377.18% in Q1 2022.
• Historically, FCF Margin has averaged 721.63% across 4 years, with a median of 645.57% in 2023.
• The largest YoY upside for FCF Margin was 86884 bps in 2023 against a maximum downside of 51411 bps in 2023.
• Oramed Pharmaceuticals' FCF Margin stood at 428.08% in 2021, then slumped by 116 bps to 925.88% in 2022, then soared by 57 bps to 393.77% in 2023, then surged by 55 bps to 176.1% in 2025.
• The last three FCF Margin figures came in at 176.1% (Q1 2025), 393.77% (Q2 2023), and 863.06% (Q1 2023), per Business Quant data.